Management

Søren Tulstrup

President and CEO

Søren Tulstrup has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG (VTX:VIFN), a Glattbrugg, Switzerland-based global pharmaceutical company with a market-leading position within chronic kidney disease, annual sales of approximately USD 1 billion and 2,000 employees. Prior to joining Vifor Pharma, he served as Senior Vice President, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase (INN: Idursulfase), an enzyme-based treatment of the rare disease Hunter syndrome. Søren has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA-targeted drugs for various therapeutic areas including cancer and rare genetic diseases. Furthermore, Søren has served in several senior commercial roles within Merck & Co., Inc. and Sandoz Pharma AG (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School. Born 1965.

Shareholding: 5,000
Share rights (max*): 86,540
ESOPs' (max*): 66,347

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Emanuel Björne

Vice President Global Business Development

Emanuel joined Hansa Medical in 2007 counting more than 15 years of operational experience from Scandinavian Pharma and Biotech industry (Biolin Scientific, Polypeptide Labs and Hansa Medical) serving as Business Analyst, Analytical Chemist and start-up CEO. Emanuel holds a M.Sc. in Engineering Physics (biophysics core) from Lund University and the University of California at Santa Barbara.

Shareholding: -
Share rights (max*): 30,545
Warrants: -

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Max Sakajja

Vice President, Corporate Strategy

Max joined Hansa Medical in 2017. He has broad corporate development background and had previously worked with corporate finance at Biovitrum/SOBI in the position of Director Mergers & Acquisitions. Before joining Hansa Medical, Max worked with strategy and business development at Envirotainer as the Global Product and Service Development Manager. Max holds an M.Sc. in Biotechnology from the Royal Institute of Technology.

Shareholding: 5,000
Share rights (max*): 30,746
Warrants: 5,000

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Eva-Maria Joed

Vice President, Finance & administration

Eva-Maria joined Hansa Medical in 2015 and brings long and wide experience within finance to the company. She has held positions both as Chief Accountant and CFO and worked in international companies such as Kemira Kemi AB, Johns Manville AB within the Berkshire Hathaway group and Procordia Food AB. She has also been responsible for implementing new financial systems and policies, and for IT. Eva-Maria holds a Master of Science in Business and Economics from Lund University.

Shareholding: 8,000
Share rights (max*): 30,545
Warrants: -

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Dr. Christian Kjellman

Senior Vice President, Chief Scientific Officer, Research and Development

Christian joined Hansa Medical in 2008 after serving at BioInvent AB as Senior Scientist focusing on novel target evaluation and antibody technology. Prior to that, he functioned as Head of Research at the biopharmaceutical development company Cartela AB, mainly focusing on novel drug target evaluation. He has extensive research experience in cell- and molecular biology and as an Assistant Professor in Molecular Genetics at Lund University. Christian holds a M.Sc. in Chemical Biology and a Ph.D. in Tumour Immunology from Lund University.

Shareholding: -
Share rights (max*): 69,801
ESOP's: -

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Henk Doude van Troostwijk

Senior Vice President, Chief Commercial Officer

Henk has extensive management experience in sales and marketing in the areas of transplantation and orphan drugs. Before joining Hansa Medical in 2016, Henk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk holds an MBA from Henley Management College at the University of Reading, UK.

Shareholding: -
Share rights (max*): 33,817
ESOP's (max): 21,231

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Karin Aschan

Vice President Regulatory Affairs

Karin joined Hansa in 2016. She has a long experience from working within Regulatory Affairs, initially at AstraZeneca, and has worked on EU and US projects in all clinical trial phases through registration up to marketing phase. Karin has held the position as Head of Regulatory Affairs at Active Biotech and at ClinicalDataCare. She has also been working as an independent regulatory consultant. Karin holds a M.Sc. in Pharmacy from Uppsala University.

Shareholding: -
Share rights (max*): -
ESOP's (max*): -

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Vincenza Nigro

Vice President, Global Medical Affairs

Vincenza holds more than two decades of international, life sciences industry expertise in medical affairs, clinical development and commercial leadership roles, including deep experience in transplantation and orphan diseases. Before joining Hansa Medical in 2018, Vincenza built and led the global medical affairs function at Veloxis Pharmaceuticals, a specialty pharmaceutical company focused on transplantation. Previously, she spent over a decade at Hoffmann- La Roche in the US in drug discovery, clinical development and commercial roles within immunology and transplantation. She has also held a commercial leadership role at US specialty pharma company Enzon Pharmaceuticals, which was focused on oncology. Ms. Nigro holds an MBA degree from Massachusetts Institute of Technology (MIT).

Shareholding: -
Share rights (max*): 16,540
ESOP's (max*): 19,108

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Anne Säfström Lanner

Vice President, Global HR

Anne joined Hansa Medical in 2019, after having served at European Spallation Source (ESS), a joint European multi-disciplinary research facility and at Cellavision, a provider of digital solutions for medical microscopy within hematology. She has held positions both as Head of HR, Head of Resourcing, HR Manager & Deputy Head of HR and has extensive experience from growing start-up international companies. Anne holds a Bachelor of Social Science in Human Resource Management, focusing in organizational development & leadership, from Lund University

Shareholding: 600
Share rights (max*): 29,618
Warrants: 2,000

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.

Donato Spota

Donato Spota

Senior Vice President, Chief Financial Officer

Donato joined Hansa Biopharma in 2019, and brings more than 20 years of pharmaceutical industry experience in international environments, including strategic finance, investor relations and international capital markets transactions to the company. Prior to joining Hansa, Donato served as Chief Financial Officer at Basilea Pharmaceutica AG. Donato holds a degree in Information Technology from the Swiss BBT (Bundesamt für Berufsbildung und Technologie) and a master’s degree in business administration from the Hochschule für Wirtschaft und Umwelt Nürtingen-Geislingen.

Shareholding: -
Share rights (max*): 23,434
ESOP's (max*): 42,642

*The possible entitlement of share rights through the incentive program LTIP2016, LTIP2018 & 2019 is the potential maximum number. Share right allocation could be lower or zero depending on the share price development.